These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 17592721)

  • 21. Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease.
    Okumiya T; Ishii S; Takenaka T; Kase R; Kamei S; Sakuraba H; Suzuki Y
    Biochem Biophys Res Commun; 1995 Sep; 214(3):1219-24. PubMed ID: 7575533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice.
    Christensen EI; Zhou Q; Sørensen SS; Rasmussen AK; Jacobsen C; Feldt-Rasmussen U; Nielsen R
    J Am Soc Nephrol; 2007 Mar; 18(3):698-706. PubMed ID: 17287429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-viral, integrin-mediated gene transfer into fibroblasts from patients with lysosomal storage diseases.
    Estruch EJ; Hart SL; Kinnon C; Winchester BG
    J Gene Med; 2001; 3(5):488-97. PubMed ID: 11601762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potential action of galactose as a "chemical chaperone": increase of beta galactosidase activity in fibroblasts from an adult GM1-gangliosidosis patient.
    Caciotti A; Donati MA; d'Azzo A; Salvioli R; Guerrini R; Zammarchi E; Morrone A
    Eur J Paediatr Neurol; 2009 Mar; 13(2):160-4. PubMed ID: 18571950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Ser-65 in the activity of alpha-galactosidase A: characterization of a point mutation (S65T) detected in a patient with Fabry disease.
    Ishii S; Suzuki Y; Fan JQ
    Arch Biochem Biophys; 2000 May; 377(2):228-33. PubMed ID: 10845698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants.
    Siekierska A; De Baets G; Reumers J; Gallardo R; Rudyak S; Broersen K; Couceiro J; Van Durme J; Schymkowitz J; Rousseau F
    J Biol Chem; 2012 Aug; 287(34):28386-97. PubMed ID: 22773828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase.
    Garman SC; Garboczi DN
    J Mol Biol; 2004 Mar; 337(2):319-35. PubMed ID: 15003450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha-galactosidase A in vascular disease.
    Bodary PF; Shayman JA; Eitzman DT
    Trends Cardiovasc Med; 2007 May; 17(4):129-33. PubMed ID: 17482095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
    Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
    Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines.
    Benjamin ER; Flanagan JJ; Schilling A; Chang HH; Agarwal L; Katz E; Wu X; Pine C; Wustman B; Desnick RJ; Lockhart DJ; Valenzano KJ
    J Inherit Metab Dis; 2009 Jun; 32(3):424-40. PubMed ID: 19387866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma.
    Froissart R; Guffon N; Vanier MT; Desnick RJ; Maire I
    Mol Genet Metab; 2003 Nov; 80(3):307-14. PubMed ID: 14680977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell-based screening of active-site specific chaperone for the treatment of Fabry disease.
    Fan JQ; Ishii S
    Methods Enzymol; 2003; 363():412-20. PubMed ID: 14579593
    [No Abstract]   [Full Text] [Related]  

  • 33. Promoter dependence of plasmid-pluronics targeted alpha galactosidase A expression in skeletal muscle of Fabry mice.
    Lavigne MD; Pohlschmidt M; Novo JF; Higgins B; Alakhov V; Lochmuller H; Sakuraba H; Goldspink G; MacDermot K; Górecki DC
    Mol Ther; 2005 Nov; 12(5):985-90. PubMed ID: 15975851
    [No Abstract]   [Full Text] [Related]  

  • 34. Rescue of mutant alpha-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes.
    Hamanaka R; Shinohara T; Yano S; Nakamura M; Yasuda A; Yokoyama S; Fan JQ; Kawasaki K; Watanabe M; Ishii S
    Biochim Biophys Acta; 2008 Jun; 1782(6):408-13. PubMed ID: 18381081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human α-galactosidase a: pharmacological chaperoning efficacy on Fabry disease mutants.
    Yu Y; Mena-Barragán T; Higaki K; Johnson JL; Drury JE; Lieberman RL; Nakasone N; Ninomiya H; Tsukimura T; Sakuraba H; Suzuki Y; Nanba E; Mellet CO; García Fernández JM; Ohno K
    ACS Chem Biol; 2014 Jul; 9(7):1460-9. PubMed ID: 24783948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease.
    Ohashi T; Iizuka S; Ida H; Eto Y
    Mol Genet Metab; 2008 Jul; 94(3):313-8. PubMed ID: 18456533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosis.
    Aguilar-Moncayo M; Takai T; Higaki K; Mena-Barragán T; Hirano Y; Yura K; Li L; Yu Y; Ninomiya H; García-Moreno MI; Ishii S; Sakakibara Y; Ohno K; Nanba E; Ortiz Mellet C; García Fernández JM; Suzuki Y
    Chem Commun (Camb); 2012 Jul; 48(52):6514-6. PubMed ID: 22618082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional and Clinical Consequences of Novel α-Galactosidase A Mutations in Fabry Disease.
    Lukas J; Scalia S; Eichler S; Pockrandt AM; Dehn N; Cozma C; Giese AK; Rolfs A
    Hum Mutat; 2016 Jan; 37(1):43-51. PubMed ID: 26415523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease.
    Porto C; Pisani A; Rosa M; Acampora E; Avolio V; Tuzzi MR; Visciano B; Gagliardo C; Materazzi S; la Marca G; Andria G; Parenti G
    J Inherit Metab Dis; 2012 May; 35(3):513-20. PubMed ID: 22187137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case study on the pathophysiology of Fabry disease: abnormalities of cellular membranes can be reversed by substrate reduction
    Brogden G; Shammas H; Maalouf K; Naim SL; Wetzel G; Amiri M; von Köckritz-Blickwede M; Das AM; Naim HY
    Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28351893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.